Skip to main content

Niagen Bioscience, Inc. (NAGE) research

Niagen Bioscience, Inc.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$2.99
As of

Niagen Bioscience, Inc. (NAGE): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-04.

As of . Source: SEC EDGAR filings for NAGE. Method and limitations.

SHARE THIS CARD

Share the NAGE intelligence card

A branded snapshot of NAGE: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion NAGE intelligence card preview
Post to X
LIVE TERMINAL

See NAGE live in the terminal

Track NAGE's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live NAGE terminal, free

Active signals for NAGE

FREE, NO ACCOUNT

Every signal on NAGE, as it fires

You are seeing 5 of 29 signals recorded on NAGE since 2026-06-05.

The five above landed across 2 days. The other 24 were recorded on 2 other days. 21 of the 29 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in NAGE (2026Q2)

Manager / securityMarket value% portfolioQoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 171077407 · 2026Q2$2.1M0.00%,
CITADEL ADVISORS LLCCUSIP 171077407 · 2026Q2$2M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 171077407 · 2026Q2$879K0.00%,
D. E. Shaw & Co., Inc.CUSIP 171077407 · 2026Q2$319K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, NAGE

NAGE mentioned in Kresmion daily briefs

NAGE against its peers

NAGE's operating margin of 12.6% ranks in the 82nd percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.

MetricNAGEPeer medianPercentilen
Revenue FY129M USD25.4M USD8213
Gross margin64.3%n/an/a2
Operating margin12.6%-251.6%8213
Net margin13.4%-229.6%8213
Return on equity22.7%-47.0%8617
P / E14.9xn/an/a1

Peers (18): ALXO, CGEN, SLGL, ADAG, YDES, WHWK, IVVD, KROS, NGEN, BCYC, AVXL, MGNX, ANTX, TRDA, NKTX, PLX, LCTX, ACIU. Left out: TNXP (no annual filing), VRXA (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NAGE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more NAGE signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NAGEand get the insider, 13F, options, and confluence read in one view.

Open the live NAGE terminal, free